BioVie reports positive Phase 2 Parkinson’s data for bezisterim
Published: 00:53 21 Oct 2026 AEDT
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association’s annual meeting in San Diego.
The randomized, double-blind, placebo-controlled trial enrolled 57 patients, who received bezisterim or placebo for 12 weeks. Researchers tracked motor and non-motor symptoms, daily functioning, sleep, inflammatory biomarkers and overall benefit, using a Composite Benefit Score (CBS).
BioVie’s Parkinson’s drug bezisterim improved symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association meeting. In this subgroup, about half of the 57-patient trial, treated patients improved on motor and non-motor scores while placebo patients worsened slightly.
Across all patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo, and the risk of meaningful worsening was about 70% lower (14% versus 46%). Adverse events were less common with the drug (39.3% versus 51.7%), with no severe or serious events in either group.
Treatment-emergent adverse events occurred in 39.3% of bezisterim patients and 51.7% of placebo patients. No severe or serious adverse events were reported in either group, and each arm had one potentially treatment-related event.
BioVie’s Clarence Ahlem said the results show an anti-inflammatory treatment can benefit both motor and non-motor symptoms, and that the findings support further development of bezisterim, including its potential to affect the underlying disease process.
The abstract was published in Annals of Neurology.